EKF Diagnostics Displays POC Analyzers for Hemoglobin, HbA1c And Lactate at MEDLAB Middle East
|
By LabMedica International staff writers Posted on 05 Feb 2020 |

Illustration
EKF Diagnostics (Cardiff, Wales, UK) showcased its full product range, including the Quo-Test A1c, Quo-Lab A1c, Hemo Control, DiaSpect Tm and Lactate Scout 4 analyzers, at MEDLAB Middle East, which took place from 3-6 February 2020 at the Dubai World Trade Centre. MEDLAB Middle East, the Middle East & North Africa (MENA) region’s largest medical laboratory exhibition and congress, drew over 25,800 medical laboratory industry professionals and 600 exhibitors from 35 countries.
EKF Diagnostics is a global medical manufacturer of point-of-care (POCT) devices and tests for hemoglobin, glycated hemoglobin (HbA1c), glucose and lactate. Its POC analyzers are designed for use within doctors' surgeries, clinics, hospitals and laboratories to provide fast and accurate results at an affordable price. EKF Central Laboratory division manufactures a wide spectrum of reagents for use in hospital laboratories across a broad portfolio of automated and semi-automated analyzers.
Among its Hemoglobin products on display at MEDLAB Middle East were the Hemo Control POC hemoglobin analyzer designed to provide quantitative, lab quality hemoglobin results from 25 seconds; DiaSpect Tm, the world’s fastest hemoglobin analyzer that delivers laboratory quality results in just about one second of the microcuvette being placed into the palm-sized analyzer; and the HemataStat II microhematocrit centrifuge that provides a quantitative hematocrit reading for up to six blood samples from one 60 second spin.
EKF Diagnostics’ Diabetes products on display at this year’s MEDLAB Middle East included the Quo-Lab HbA1c semi-automated desktop POC analyzer for measuring glycated hemoglobin (HbA1c); and the Quo-Test fully automated desktop POC analyzer designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a POC setting such as diabetes clinics and doctors’ surgeries. In the Sports segment, EKF Diagnostics displayed the Lactate Scout 4 handheld analyzer that requires a very small blood sample to deliver lactate measurement in 10 seconds and is programmed with step-testing features designed to improve athletic performance over time.
Related Links:
EKF Diagnostics
EKF Diagnostics is a global medical manufacturer of point-of-care (POCT) devices and tests for hemoglobin, glycated hemoglobin (HbA1c), glucose and lactate. Its POC analyzers are designed for use within doctors' surgeries, clinics, hospitals and laboratories to provide fast and accurate results at an affordable price. EKF Central Laboratory division manufactures a wide spectrum of reagents for use in hospital laboratories across a broad portfolio of automated and semi-automated analyzers.
Among its Hemoglobin products on display at MEDLAB Middle East were the Hemo Control POC hemoglobin analyzer designed to provide quantitative, lab quality hemoglobin results from 25 seconds; DiaSpect Tm, the world’s fastest hemoglobin analyzer that delivers laboratory quality results in just about one second of the microcuvette being placed into the palm-sized analyzer; and the HemataStat II microhematocrit centrifuge that provides a quantitative hematocrit reading for up to six blood samples from one 60 second spin.
EKF Diagnostics’ Diabetes products on display at this year’s MEDLAB Middle East included the Quo-Lab HbA1c semi-automated desktop POC analyzer for measuring glycated hemoglobin (HbA1c); and the Quo-Test fully automated desktop POC analyzer designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a POC setting such as diabetes clinics and doctors’ surgeries. In the Sports segment, EKF Diagnostics displayed the Lactate Scout 4 handheld analyzer that requires a very small blood sample to deliver lactate measurement in 10 seconds and is programmed with step-testing features designed to improve athletic performance over time.
Related Links:
EKF Diagnostics
Latest MEDLAB 2020 News
- Diagnostica Stago Displays STA Compact Max and STA Satellite Max Analyzers at MEDLAB
- DAS Srl Exhibits Range of Fully Automated Systems at MEDLAB Middle East 2020
- GeneMatrix Promotes Sex and Respiratory Infection Testing Products at MEDLAB
- Mindray Showcases Comprehensive IVD Solutions Portfolio at MEDLAB Middle East 2020
- New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020
- Vircell Exhibits Its New VirClia Lotus and qSPEED-OLIGO Systems at MEDLAB
- Randox Showcases New All-In-One Solution for Molecular Diagnostics at MEDLAB Middle East 2020
- Erba Mannheim Launches New Electrolyte Analyzer with Maintenance-free Electrodes at MEDLAB 2020
- MEDLAB Middle East 2020 Addresses Future of Laboratory Medicine
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more









